View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

Edison issues update on Gresham House Energy Storage Fund (GRID): Focu...

Edison Investment Research Limited Edison issues update on Gresham House Energy Storage Fund (GRID): Focused on revenues and project completions 20-May-2024 / 08:50 GMT/BST The issuer is solely responsible for the content of this announcement.   London, UK, 20 Mai 2024   Edison issues update on Gresham House Energy Storage Fund (GRID): Focused on revenues and project completions Gresham House Energy Storage Fund (GRID) invests in utility-scale battery energy storage systems (BESS) in Great Britain. GRID and its peers saw sharp share price falls in H223 and early 2024, due mos...

Zeta Global Holdings Corp: 1 director

A director at Zeta Global Holdings Corp sold 166,667 shares at 17.100USD and the significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ye...

 PRESS RELEASE

Start of construction work on the Uus-Kindrali

Start of construction work on the Uus-Kindrali Start of construction work on the Uus-Kindrali Pro Kapital has started the construction of the next phase of the Kindrali Houses project in Tallinn Kristiine City. The building at Talli 3/Sammu 8, which is part of the Uus-Kindrali project, will comprise 90 apartments and one commercial unit. The new phase of Kindrali Houses will consist of a 7-storey building with 1-5 bedroom apartments. To date, 31% of the apartments have already been pre-sold, which was the incentive to start construction work. Uus-Kindrali, with its modern ...

 PRESS RELEASE

Uus-Kindrali ehitustöödega alustamine

Uus-Kindrali ehitustöödega alustamine   Uus-Kindrali ehitustöödega alustamine Pro Kapital alustas Tallinnas Kristiine Citys Kindrali Majade projekti järgmise etapi ehitustöid, mille käigus valmib 90 korteri ja ühe äripinnaga Uus-Kindrali projekti esimene elamu aadressil Talli 3/Sammu 8. Kindrali Majade uue etapi käigus ehitatav hoone on 7-korruseline, majas on 1-5 toalised korterid. Tänaseks on eelmüügis realiseeritud juba 31% korteritest ning see oli ka ajendiks ehitustöödega alustamiseks. Kristiine Citysse kerkivate kaasaegsete ja skandinaavialiku arhitektuuriga...

 PRESS RELEASE

Start of construction work on the Uus-Kindrali

Start of construction work on the Uus-Kindrali   Start of construction work on the Uus-Kindrali Pro Kapital has started the construction of the next phase of the Kindrali Houses project in Tallinn Kristiine City. The building at Talli 3/Sammu 8, which is part of the Uus-Kindrali project, will comprise 90 apartments and one commercial unit. The new phase of Kindrali Houses will consist of a 7-storey building with 1-5 bedroom apartments. To date, 31% of the apartments have already been pre-sold, which was the incentive to start construction work. Uus-Kindr...

Carole Braudeau
  • Carole Braudeau

Morning Crédit 20/05/2024

Moody’s relève le rating d’Ontex à B2 Atos : les créanciers obligataires rejettent l’offre de Daniel Kretinsky (La Tribune)>...

Carole Braudeau
  • Carole Braudeau

Credit Morning 05/20/2024

Moody’s upgrades Ontex to B2Atos: bondholders reject Daniel Kretinsky’s offer (La Tribune)>...

Roelof-Jan van den Akker
  • Roelof-Jan van den Akker

Technical Analysis/Bund future

Mixed signals in the weekly chart shows that we are still within the bottoming process. Prices exceeded the high of the week before last week at 131.86 by making a new high at 132.06. However, last week's close at 130.69 is disappointing as it ended 19bp lower and off the highs at 132.06. This suggests that confirmation of a bottom is still required and the focus should again be on support after this weakness. Solid support in the weekly chart between 129.85 and 129.10 with the April low at 129....

Next Vision Stabilized Systems Ltd: 3 directors

Three Directors at Next Vision Stabilized Systems Ltd sold 1,245,359 shares at between 55.700ILS and 57.914ILS. The significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the compa...

Agile Content S.A.: 1 director

A director at Agile Content S.A. bought 6,000 shares at 4.300EUR and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...

E-Globe S.p.A: 1 director

A director at E-Globe S.p.A bought 15,000 shares at 1.424EUR and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...

GPI S.p.A.: 1 director

A director at GPI S.p.A. bought 4,500 shares at 13.116EUR and the significance rating of the trade was 56/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...

Peter Low
  • Peter Low

Progroup - Earnings Flash - Q1 FY 2024 Results - Lucror Analytics

Progroup reported very soft Q1/24 numbers last week, with sales down 17.1% y-o-y and EBITDA slumping 58.1% owing to lower prices. Cash flow was weak due to capex. Net leverage rose 1.2x q-o-q to 4.4x. We expect net leverage to stay elevated in the low 4x region this year, owing to EBITDA decline and cash burn. . To request full and unrestricted access to Lucror’s research and analytics platform, please visit

Marc Zwartsenburg ... (+2)
  • Marc Zwartsenburg
  • CEFA

ING Benelux Favourites/Weekly performance and valuation update

The ING Benelux Favourites list comprises ASM International, ASR, DEME Group, D'Ieteren, Fugro, OCI, Randstad and UCB.

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Alexander Krämer
Stephane Foucaud
  • Stephane Foucaud

Chariot Limited (AIM: CHAR): Drilling at the second well onshore Moroc...

• Chariot has started to drill the Dartois prospect onshore Morocco. The well is targeting a different reservoir system and trapping style than the Gaufrette prospect. • The main target at Dartois is estimated to hold 12 bcf of gross prospective resources. Success would de-risk a total of 20 bcf of gross prospective resources (+8 bcf) in the Dartois area. • A rig-less well test would be run in case of success. • Our unrisked NAV for the well is £0.05 per share with a ReNAV of £0.02 per share....

Sean Conroy
  • Sean Conroy

Immix Biopharma - All roads lead to NEXICART-2

Immix Biopharma’s Q124 report reflected a period focused on its lead CAR-T asset, NXC-201, targeting amyloid light chain amyloidosis (ALA), which was recently bolstered by incremental NEXICART-1 data. The quarter saw a pick-up in preparatory activities in advance of the US NEXICART-2 trial initiation with the finalization of a manufacturing facility in California and selection of the lead clinical trial site. We await the first-patient dosing, expected in mid-2024. We also expect an update on th...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch